Form 8-K - Current report:
SEC Accession No. 0001437749-24-037520
Filing Date
2024-12-16
Accepted
2024-12-16 08:10:18
Documents
16
Period of Report
2024-12-16
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20241215_8k.htm   iXBRL 8-K 46816
2 EXHIBIT 99.1 ex_757662.htm EX-99.1 30496
7 img01.jpg GRAPHIC 856
  Complete submission text file 0001437749-24-037520.txt   242858

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvph-20241216.xsd EX-101.SCH 3915
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20241216_def.xml EX-101.DEF 13861
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20241216_lab.xml EX-101.LAB 18286
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20241216_pre.xml EX-101.PRE 13893
18 EXTRACTED XBRL INSTANCE DOCUMENT rvph20241215_8k_htm.xml XML 4976
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 241550184
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)